Management of Cardiac Arrhythmias with Tiapamil
| Autor: | B. Brisse, H. Bramann, F. Bender, G. Schwippe, H. Kuhs |
|---|---|
| Rok vydání: | 1982 |
| Předmět: |
Adult
Male medicine.medical_specialty Ventricular rate Heart Conduction System Internal medicine Atrial Fibrillation Humans Medicine Chronic atrial fibrillation Infusions Parenteral Pharmacology (medical) In patient Propylamines business.industry Tiapamil Hydrochloride Arrhythmias Cardiac Middle Aged Premature Beats Calcium Channel Blockers Anesthesia Injections Intravenous cardiovascular system Cardiology Female Antiarrhythmic effect Ventricular premature beats Hypotension Cardiology and Cardiovascular Medicine business Anti-Arrhythmia Agents |
| Zdroj: | Cardiology. 69:144-148 |
| ISSN: | 1421-9751 0008-6312 |
| DOI: | 10.1159/000173548 |
| Popis: | 37 patients with either chronic atrial fibrillation (AF), atrial premature beats (APBs) or ventricular premature beats (VPBs) received tiapamil as antiarrhythmic treatment. Tiapamil reduced A-V conduction by an average 20% in the group with AF (10 patients), the magnitude of response being dependent on the initial ventricular rate. In 3 of the 7 patients with APBs, the frequency of ectopic beats was reduced following a single i.v. injection of 1 mg/kg tiapamil. In patients with VPBs (n = 20), tiapamil (i.v. injection of 1 mg/kg followed by 4-hour i.v. infusion of 50 micrograms/kg/min in 10 patients) reduced ectopic beats by 30-50% in 6 cases, these all being patients who had not responded to previous antiarrhythmic therapy. The antiarrhythmic effect was maintained by i.v. infusion of 50 micrograms/kg/min for 4 h. The antiarrhythmic effect of tiapamil consists essentially in slowing A-V conduction and reducing chronic VPBs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|